Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MyNano

Financiado

Towards the design of Personalised Polymer based Combination Nanomedicines for A...

Towards the design of Personalised Polymer based Combination Nanomedicines for Advanced Stage Breast Cancer Patients Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted comb... ver más

31/12/2020

Fundación de la Co...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

Fundación de la Comunidad Valenciana Centro d... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100%

2 Participantes

Fundación de la Comunidad Va...

1.72M€ | Lider

EQUIPOS NUCLEARES SA SME

547.74K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CTQ2010-18195 NANOFARMACOS POLIMERICOS UTILIZADOS COMO AGENTES SIMPLES Y E... 120K€ Cerrado

PDC2021-120929-I00 ESTUDIO DE PRUEBA DE CONCEPTO DE UNA NUEVA NANOTERAPIA ONCOL... 150K€ Cerrado

SAF2013-44848-R POLIMEROS TERAPEUTICOS COMO AGENTES SIMPLES Y EN COMBINACION... 218K€ Cerrado

RTI2018-093831-B-I00 SISTEMAS MULTIVALENTES PARA NANOMEDICINA 182K€ Cerrado

PDC2022-133036-I00 NANOABRICACION ESCALADA DE NANOCAPSULAS MAGNETOPLASMONICAS P... 150K€ Cerrado

PID2021-125910OB-I00 DESARROLLO DE NANOPARTICULAS ZWITERIONICAS DE POLI(BETA-AMIN... 213K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2015-05-05
Fecha Fin: 2020-12-31

Líder del proyecto

Fundación de la Comunidad Valenciana Centro d... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 130K€

Presupuesto del proyecto 2M€

Descripción del proyecto Research on anticancer therapies has provided little progress towards improved survival rates for patients with metastatic disease. The intrinsic advantages of polymer conjugates can be optimised to rationally design targeted combination therapies, concept I pioneered that allows enhanced therapeutic efficiency. Early clinical trials involving conjugates showed activity in chemotherapy refractory patients and reduced drug-related toxicity. However, there is a growing concern on patient variability regarding tumor patho-physiology that underlie successful therapeutic outcome. Specific biomarkers are required to select those patients most likely to show good clinical response to these therapies. The objective of MyNano is to engineer polymer-based combination therapies designed to treat metastatic breast cancer in a patient personalised manner. Therefore, novel multicomponent polymer conjugates with precise control over size, shape, solution conformation, multifunctionality and bioresponsiveness will be obtained while in parallel their structure activity relationships to underlying proposed mechanisms of action in clinically relevant models will be studied. Polyglutamates obtained by controlled polymerisation and self-assembly strategies will be the carriers. Primary breast cancer patient tissue will be used to generate cell and in vivo models representing different clinical molecular subtypes. MyNano will also investigate new combination strategies using current treatments together with inhibitors of tumor-derived exosome release pathways, phenomenon related to metastasis and resistance mechanisms. The aim is to provide a novel methodological approach that would allow by reiterative design to optimise the design of the next generation nanoconjugates for the treatment of specific metastatic cancer clinical subtypes. MyNano will be a breakthrough as it introduces a paradigm shift in the strategy to design nanomedicines in areas of unmet clinical need.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores